These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. Sdringola S; Nakagawa K; Nakagawa Y; Yusuf SW; Boccalandro F; Mullani N; Haynie M; Hess MJ; Gould KL J Am Coll Cardiol; 2003 Jan; 41(2):263-72. PubMed ID: 12535820 [TBL] [Abstract][Full Text] [Related]
8. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. Borgia MC; Medici F Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525 [TBL] [Abstract][Full Text] [Related]
9. Treatment of diabetic dyslipidemia. Garg A Am J Cardiol; 1998 Feb; 81(4A):47B-51B. PubMed ID: 9526814 [TBL] [Abstract][Full Text] [Related]
14. Selection of appropriate type and intensity of lipid-lowering therapy. Tikkanen MJ Curr Opin Lipidol; 1995 Dec; 6(6):360-4. PubMed ID: 8750248 [TBL] [Abstract][Full Text] [Related]
15. Optimal management of cholesterol levels and the prevention of coronary heart disease in women. Mosca LJ Am Fam Physician; 2002 Jan; 65(2):217-26. PubMed ID: 11820486 [TBL] [Abstract][Full Text] [Related]
16. [Prevention of coronary heart disease by therapy of hyperlipidemia. Between cholesterol hysteria and therapeutic realism]. Deller M; Huth K Fortschr Med; 1992 Sep; 110(25):463-6. PubMed ID: 1398397 [TBL] [Abstract][Full Text] [Related]
17. Rationale for treatment. Gotto AM Am J Med; 1991 Jul; 91(1B):31S-36S. PubMed ID: 1867234 [TBL] [Abstract][Full Text] [Related]
18. [Coronary risk in Spain and its treatment with lipid-lowering drugs]. Maiques Galán A; Villar Alvarez F; Llor Vila C; Torcal Laguna J Aten Primaria; 2003 Oct; 32(7):420-2. PubMed ID: 14622555 [No Abstract] [Full Text] [Related]
19. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D; Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149 [TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]